Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Neuroprotective and antioxidant phenazines designed at Nippon Chemiphar

Sep. 4, 1998

Regeneron receives milestone payment from Sumitomo related to BDNF development

Sep. 4, 1998

Pfizer/Neurogen anxiolytic advances in clinical trials

Sep. 3, 1998

Pharmacological profile of new acetylcholinesterase inhibitor: T-82

Sep. 3, 1998

Therapeutics for cerebrovascular disorders in development at Nippon Chemiphar

Sep. 3, 1998

Compounds interacting with nicotinic receptors for cognitive and memory deficits

Sep. 2, 1998

Anticonvulsant benzamides prepared at SKB

Sep. 2, 1998

Cambridge NeuroScience announces advances in MS program

Sep. 2, 1998

Betaseron to receive fast track review in Canada

Sep. 2, 1998

Lamotrigine approved for new indication in the U.S.: Lennox-Gastaut syndrome

Sep. 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...